Clinical Efficacy of Zoledronic Acid on Osteoporosis and Back Pain of Postmenopausal Women

YU Bin; XIA Yingpeng; DU Wenjun; LI Huinan; GAO Junwei

Abstract：Objective To evaluate the clinical efficacy of 5mg of zoledronic acid in the treatment of osteoporosis and back pain of postmenopausal women.Methods Randomized comparative study was taken.From April 2012 to April 2013, a total of 84 patients with osteoporosis and back pain were randomly divided into experimental group and control group, with 42 cases in each group.All the patients were continually treated with 600mg of calcium, Vitamin D 124 IU/d and calcitriol 0.25 μg/d for one year.Patients of ex-perimental group received 5mg zoledronic acid once.The lumbar spine (LS) and total hip (TP) bone mineral density (BMD), blood calcium, X-ray examination of thoracolumbar spine, VAS pain sore and ODI were carried out before treatment and after treatment for 12 months.Results 39 patients in experimental group and 40 patients in control group were followed up for more than 12 months.In experimental group, BMD of LS increased by 5.8%, TP by 3.5%, with significant difference.In control group, BMD of LS and TP increased by 2.0% and 1.4% with significant difference.The increases of MBD (both LS and TP) of experimental group were greater than those in control group, and the difference was statistically significant.After 12 months, VAS scores, ODI scores, the increase of VAS and ODI in experimental group were greater than those in control group, and the difference was statistically significant.There were no new clinical vertebral fractures in both groups and no serious adverse reactions in experimental group.Conclusion A once-yearly use of zoledronic acid (5 mg) can significantly increase the BMD of lumbar spine and hip, and released back pain prominently. With the good compliance and tolerance of patients, zoledronic acid (5 mg) is an important means of treating osteoporosis.